Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Holdings Raised by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC increased its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 112.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 421,782 shares of the company’s stock after acquiring an additional 223,155 shares during the period. Keros Therapeutics comprises approximately 3.1% of Parkman Healthcare Partners LLC’s holdings, making the stock its 5th largest position. Parkman Healthcare Partners LLC’s holdings in Keros Therapeutics were worth $24,493,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in KROS. FMR LLC raised its stake in shares of Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after purchasing an additional 179,374 shares during the last quarter. Alkeon Capital Management LLC increased its holdings in Keros Therapeutics by 18.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after buying an additional 298,694 shares in the last quarter. Darwin Global Management Ltd. raised its position in Keros Therapeutics by 6.3% in the 2nd quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock worth $68,772,000 after buying an additional 89,952 shares during the last quarter. Holocene Advisors LP lifted its stake in Keros Therapeutics by 22.5% during the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock valued at $48,959,000 after acquiring an additional 154,784 shares during the period. Finally, Nantahala Capital Management LLC boosted its holdings in shares of Keros Therapeutics by 28.8% during the 2nd quarter. Nantahala Capital Management LLC now owns 378,807 shares of the company’s stock valued at $17,311,000 after acquiring an additional 84,810 shares during the last quarter. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Stock Up 9.8 %

KROS stock opened at $62.28 on Wednesday. The business’s 50-day moving average price is $59.67 and its 200-day moving average price is $52.37. The stock has a market cap of $2.52 billion, a P/E ratio of -11.95 and a beta of 1.20. Keros Therapeutics, Inc. has a twelve month low of $27.31 and a twelve month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.33) EPS. On average, equities research analysts expect that Keros Therapeutics, Inc. will post -5.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KROS has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a report on Thursday, November 7th. Scotiabank assumed coverage on Keros Therapeutics in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price target on the stock. Guggenheim initiated coverage on Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target on the stock. Jefferies Financial Group initiated coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating for the company. Finally, Wedbush reissued an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat, Keros Therapeutics has an average rating of “Buy” and an average price target of $88.89.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.